| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2019-08-06 |
Genprex (USA - TX) Aldevron (USA -MA) |
TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA |
|
manufacturing - production |
Cancer - Oncology - Technology - Services |
Production agreement |
| 2019-07-31 |
RegenXBio (USA - MD) Pfizer (USA - NY) |
NAV AAV9 vector |
Friedreich's ataxia |
licensing |
Rare diseases - Genetic diseases - Neurodegenerative diseases |
Licensing agreement |
| 2019-07-30 |
Alnylam Therapeutics (USA - MA) GENESIS Pharma (Cyprus) |
Onpattro® |
transthyretin (TTR)-familial amyloid polyneuropathy (FAP) hereditary transthyretin-mediated amyloidosis (hATTR) |
commercialisation |
Rare diseases - Genetic diseases |
Commercialisation agreement |
| 2019-07-24 |
RegenXBio (USA - MD) Neurimmune (Switzerland) |
- AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chronic neurodegenerative diseases, including tauopathies.
|
chronic neurodegenerative diseases, including tauopathies |
development - licensing |
Neurodegenerative diseases |
Development agreement |
| 2019-07-16 |
Catalent Biologics (USA - NJ) Avexis;,a Novartis company (Switzerland) |
Zolgensma® (onasemnogene abeparvovec-xioi) |
spinal muscular atrophy (SMA) |
production - manufacturing |
Rare diseases - Neurodegenerative diseases - Neurological diseases |
Production agreement |
| 2019-07-16 |
Servier (France) Pall (USA - NY) |
End-to-end solutions for Gidy biomanufacturing facility. |
|
services contract |
|
Services contract |
| 2019-07-16 |
Alnylam Therapeutics (USA - MA) 23andMe (USA - CA) |
23andMe Health + Ancestry kits |
transthyretin-mediated amyloidosis (ATTR) |
collaboration |
Rare diseases - Genetic diseases |
Collaboration agreement |
| 2019-07-02 |
Amicus Therapeutics (USA - NJ) Paragon Gene Therapy, a unit of Catalent (USA - NJ) |
multiple active preclinical lysosomal disorder programs |
Pompe disease |
manufacturing - production |
Rare diseases - Genetic diseases |
Production agreement |
| 2019-07-01 |
Amicus Therapeutics (USA - NJ) Brammer Bio, a part of Thermo Fisher Scientific (USA - MA) |
intrathecal AAV Batten disease gene therapy programs and other AAV gene therapy programs |
Batten disease |
development - manufacturing - production |
Rare diseases - Genetic diseases - Neurological diseases - Technology - Services |
Production agreement |
| 2019-06-26 |
3P Pharmaceuticals (Spain) Nordic Nanovector (Denmark) |
Betalutin™ (177Lu-tetraxetan-tetulomab) |
B-cell non-Hodgkin lymphoma (NHL) |
production - manufacturing |
Cancer - Oncology |
Production agreement |
| 2019-06-24 |
Noxxon Pharma (Germany) undisclosedd top-10 pharmaceutical company |
NOX-A12 |
undisclosed |
|
undisclosed |
Licensing agreement |
| 2019-06-21 |
Biomarin Pharmaceutical (USA - CA) Medivation (USA - CA), now Pfizer (USA - NY) |
talazoparib (BMN 673) |
metastatic breast cancer. |
product acquisition |
Cancer - Oncology |
Milestone |
| 2019-06-20 |
Yposkesi (France) Axovant (Switzerland - USA) |
cGMP grade viral vector production |
|
development, manufacturing, production |
Rare diseases - Genetic diseases - Technology - Services |
Development agreement |
| 2019-06-19 |
Gensight Biologics (France) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Nomination |
| 2019-06-13 |
Amicus Therapeutics (USA - NJ) |
Senior Vice President of Discovery Research and Gene Therapy Science - Senior Vice President of International |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2019-06-06 |
3P Pharmaceutical (Spain) Affibody (Sweden) |
undisclosed recombinant protein |
undisclosed |
production - manufacturing |
Technology - Services |
Production agreement |
| 2019-06-05 |
Yposkesi (France) Servier (France) |
lentiviral vectors |
|
manufacturing - production |
Technology - Services |
Production agreement |
| 2019-05-29 |
Amicus Therapeutics (USA - NJ) University of Pennsylvania (USA - PA) |
AAV-based gene therapies |
Pompe disease, Fabry disease, CDKL5 deficiency disorder (CDD), Niemann-Pick Type C (NPC), mucopolysaccharidosis Type IIIB (MPS IIIB), mucopolysaccharidosis Type IIIA (MPS IIIA) |
R&D - research -development |
Rare diseases - Genetic diseases - Metabolic diseases |
Development agreement |
| 2019-05-29 |
Alnylam Therapeutics (USA - MA) |
chief scientific officer(CSO) |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2019-05-29 |
Anchiano Therapeutics (USA - MA) |
head of business development |
|
nomination |
Cancer - Oncology |
Nomination |
